Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgGl) in Postmenopausal Women

Journal of Bone and Mineral Research

Volumn 24, Issue 4, 2009, Pages 744-752

  Ruckle, Jon ^a   Jacobs, Mark ^a   Kramer, William ^b   Pearsall, Amelia E ^c   Kumar, Ravindra ^c   Underwood, Kathryn W ^c   Seehra, Jasbir ^c   Yang, Yijun ^c   Condon, Carolyn H ^c   Sherman, Matthew L ^c,d  

^a Covance Clinical Research ^*  (United States)

^b Kramer Consulting LLC   (United States)

^c Acceleron Pharma   (United States)

^d NONE   (United States)

Author keywords

ACE 011; Activin; Anabolic; Bone biomarkers; Osteoporosis

Indexed keywords

ACE 011; ACTIVIN; ACTIVIN 2A RECEPTOR; ACTIVIN RECEPTOR; ACTIVIN RECEPTOR 2A IMMUNOGLOBULIN 1; ALKALINE PHOSPHATASE BONE ISOENZYME; CARBOXY TERMINAL TELOPEPTIDE; FOLLITROPIN; HYBRID PROTEIN; IMMUNOGLOBULIN G1; PLACEBO; PROTEIN; TRACP 5B PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOLOGICAL ACTIVITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLITROPIN BLOOD LEVEL; HEADACHE; HUMAN; INJECTION SITE BLEEDING; INJECTION SITE REACTION; NORMAL HUMAN; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TOOTH PAIN;

AGED; BIOLOGICAL MARKERS; BONE RESORPTION; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; OSTEOGENESIS; PLACEBOS; POSTMENOPAUSE; RECOMBINANT FUSION PROTEINS;

EID: 65549147617     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.081208     Document Type: Article

References (37)

1. Vale W, Rivier J, Vaughan J, McClintock R, Corrigan A, Woo W, Karr D, Spiess J 1986 Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature 321:776-779.
2. Ling N. Ting S, Ueno N, Shimasaki S, Esch F, Hotta M, Guillemin R 1986 Pituitary FSH is released by a heterodimer of the β-subunits from the two forms of inhibin. Nature 321:779-782.
3. Shiozaki M, Sakai R, Tabuchi M, Nakamura T, Sugino K, Sugino H, Eto Y 1992 Evidence for the participation of endogenous activin A/erythroid differentiation factor in the regulation of erythropoiesis. Proc Natl Acad Sci USA 89:1553-1556.
4. Centrella M. McCarthy TL, Canalis E 1991 Activin-A binding and biochemical effects in osteoblast-enriched cultures from fetal-rat parietal bone. Mol Cell Biol 11:250-258.
5. Ogawa Y, Schmidt DK, Nathan RM. Armstrong RM, Miller KL, Sawamura SJ, Ziman JM. Erickson KL. de Leon ER, Rosen DM, Seyedin SM, Glaser CB. Chang RJ, Corrigan AZ, Vale W 1992 Bovine bone activin enhances bone morphogenetic protein-induced ectopic bone formation. J Biol Chem 267:14233-14237.
6. Hashimoto M, Shoda A, Inoue S. Yamada R, Kondo T, Sa- kurai T, Ueno N, Muramatsu M 1992 Functional regulation of osteoblastic cells by the interaction of activin-A with follistatin. J Biol Chem 267:4999-5004.
7. Oue Y, Kanatani H, Kiyoki M, Eto Y, Ogata E, Matsumoto T 1994 Effect of local injection of activin A on bone formation in newborn rats. Bone 15:361-366.
8. Gaddy-Kurten D. Coker JK, Abe E. Jilka RL, Manolagas SC 2002 Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures. Endocrinology 143:74-83.
9. Sakai R, Fujita S, Horie T, Ohyama K. Miwa T. Maki T, Okimoto N, Nakamura T, Eto Y 2000 Activin increases bone mass and mechanical strength of lumbar vertebrae in aged ovariectomized rats. Bone 27:91-96.
10. Ikenoue T. Jingushi S, Urabe K. Okazaki K, Iwamoto Y 1999 Inhibitory effects of activin-A on osteoblast differentiation during cultures of fetal rat calvarial cells. J Cell Biochem 75:206-214.
11. Sakai R, Eto Y, Ohtsuka M, Hirafuji M, Shinoda H 1993 Activin enhances osteoclast-like cell formation in vitro. Biochem Biophys Res Commun 195:39-46.
12. Sugatani T. Alvarez UM, Hruska KA 2003 Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. J Cell Biochem 90:59-67.
13. Fuller K, Bayley KE, Chambers TJ 2000 Activin A is an essential cofactor for osteoclast induction. Biochem Biophys Res Commun 268:2-7.
14. Perrien DS, Akel NS, Edwards PK, Carver AA. Bendre MS, Swain FL, Skinner RA, Hogue WR, Nicks KM, Pierson TM. Suva LJ, Gaddy D 2007 Inhibin A is an endocrine stimulator of bone mass and strength. Endocrinology 148:1654- 1665.
15. del Re E, Sidis Y. Fabrizio DA, Lin HY, Schneyer A 2004 Reconstitution and analysis of soluble inhibin and activin receptor complexes in a cell-free system. J Biol Chem 279: 53126-53135.
16. Pearsall RS, Canalis E, Quisel JD, Cornwall-Brady M, Underwood K, Haigis B, Ucran J, Kumar R, Pobre E, Grinberg A, Werner E, Glatt V, Stadmeyer L, Smith D, Seehra J, Bouxsein M 2008 A soluble activin type IIA receptor induces bone formation and improves skeletal integritv. Proc Natl Acad Sci USA 105:7082-7087.
17. Mangini M, Cornwall-Brady M, Pullen A, Halley K, Monnell T, Millig J, Haigis B, Kumar R, Underwood K, Pearsall RS 2007 RAP-011 (a soluble activin receptor type IIA) increases bone mineral density in combination with prior antiresorptive therapy. 29th Annual Meeting of the ASBMR. Honolulu. HI. USA, September 16-19, 2007.
18. Chantry A, Heath D, Coulton L, Gallagher O. Evans H, Eminson D. Seehra J, Vanderkerken K, Croucher PI 2007 A soluble activin receptor type IIA prevents myeloma bone disease. Xlth International Myeloma Workshop, Kos. Greece, June 25-30, 2002.
19. Bjarnason NH. Henriksen EE, Alexandersen P. Christgau S, Henriksen DB. Christiansen C 2002 Mechanism of circadian variation in bone resorption. Bone 30:307-313.
20. Prior JC 1998 Perimenopause: The complex endocrinology of the menopausal transition. Endocr Rev 19:397-428.
21. Sun L, Peng Y. Sharrow AC, Iqbal J. Zhang Z, Papachristou DJ. Zaidi S, Zhu LL. Yaroslavskiy BB, Zhou H, Zallone A. Sairam MR. Kumar TR, Bo W. Braun J, Cardoso-Landa L, Schaffler MB. Moonga BS, Blair HC, Zaidi M 2006 FSH directly regulates bone mass. Cell 123:247-260.
22. Rosen CJ 2005 Postmenopausal osteoporosis. N Engl J Med 353:595-603.
23. Cretner S, Garnero P 2006 Biochemical markers of hone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease - potential uses and pitfalls. Drugs 66:2031-2058.
24. Seeman E, Delmas PD 2006 Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 354:2250-2261.
25. de Groen PL. Lubbe DF, Hirsch LJ. Daifotis A. Stephenson W. Freedholm D. Pryor TS, Seleznick MJ, Pinkas H, Wang KK 1996 Esophagitis associated with the use of alendronate. N Engl J Med 335:1016-1021.
26. Ettinger B. Pressman A, Schein J 1998 Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care 4:1377-1382.
27. Bamias A, Kastritis E, Bamia C. Moulopoulos LA. Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E. Dimopoulos MA 2005 Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 23:8580-8587.
28. Badros A, Weikel D. Salama A, Goloubeva O. Schneider A, Rapoport A, Fenlon R, Gahres N. Sausville E, Ord R, Meiller T 2006 Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 24:945-952.
29. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Ja- gannath S, Orlowski RZ, Roodman DG, Twilde P, Anderson K 2007 American society of clinical oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25:2464-2472.
30. Grady D, Gebretsadik T, Kerlikowske K, Ernster V. Petitti D 1995 Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 85:304-313.
31. Speroff L, Rowan J, Symons J, Genant H. Wilborn W 1996 The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study): A randomized controlled trial. JAMA 276:1397-1403.
32. Overgaard K, Hansen MA, Jensen SB, Christiansen C 1992 Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study. BMJ 305:556-561.
33. Delmas PD. Bjarnason NH, Mitlak BH, Ravoux AC. Shah AS. Huster WJ. Draper M, Christiansen C 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647.
34. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA. Reginster JY, Hodsman AB, Erikscn EF, Ish-Shalom S. Genant HK. Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post-menopausal women with osteoporosis. N Engl J Med 344:1434-1441.
35. Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste- Marie LG, Gallagher JC. Pavo I, Wang J, Eriksen EF 2005 Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90:3970-3977.
36. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilesikian JP, Rosen CJ 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215.
37. Forteo 2008 Forteo labeling information. Available at http://pi.lilly.com/us/forteo-pi.pdf. Accessed April 22, 2008.